Weekly Taxotere and cisplatin with continuous-infusion 5-fluoruracil for the treatment of advanced gastric and esophageal cancer: A prospective, observational, single-institution experience

Gastric Cancer

Volumn 15, Issue 1, 2012, Pages 106-110

  Piacentini, Paolo ^a   Durante, Emilia ^a   Trolese, Annarita ^a   Mercanti, Anna ^a   Bonetti, Andrea ^a  

^a Mater Salutis Hospital   (Italy)

Author keywords

5 fluorouracil; Advanced gastric and esophageal cancer; Cisplatin; Taxotere

Indexed keywords

CAPECITABINE; CISPLATIN; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; MAGNESIUM SULFATE; METOCLOPRAMIDE; OXALIPLATIN; SEROTONIN 3 ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL STUDY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; HYDRATION; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SINGLE DRUG DOSE; SKIN; STOMACH CANCER; THERAPY DELAY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 84861526119     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-011-0078-5     Document Type: Article

References (20)

1. Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993;72:47-51.
2. Pyrhönen S, Kuitunen T, Nyandoto P, et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71:587-91.
3. Scheithauer W, Kornek G, Hejna M, et al. Palliative chemotherapy versus best supportive care in patients with metastatic gastric cancer: a randomized trial. Ann Hematol. 1994;73:A181 (suppl 2, abstr).
4. Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8:1-6.
5. Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010;(3):CD004064. doi:10.1002/14651858.CD004064.pub3.
6. Sulkes A, Smyth J, Sessa C, et al. Docetaxel (TaxotereTM) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer. 1994;70:380-3.
7. Mavroudis D, Kourousis C, Androulakis N, et al. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial. Am J Clin Oncol. 2000;23:341-4. (Pubitemid 32429142)
8. Graziano F, Catalano V, Baldelli AM, et al. A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol. 2000;11:1263-6.
9. Roth AD, Maibach R, Martinelli G, et al. Docetaxel (Taxotere)- cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol. 2000;11:301-6. (Pubitemid 30214667)
10. Ridwelski K, Gebauer T, Fahlke J, et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol. 2001;12:47-51. (Pubitemid 32162447)
11. Van Cutsem E, Moiseyenko WM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006;24:4991-7. (Pubitemid 46631401)
12. Hryniuk W, Bush H. The importance of dose intensity of chemotherapy of metastatic breast cancer. J Clin Oncol. 1984;2: 1281-8. (Pubitemid 15202705)
13. Al-Batran SE, Ajani JA. Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer. 2010;116:2511-8.
14. Roth AD, Fazio N, Stupp R, et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007;25(22):3217-23. (Pubitemid 47325604)
15. Sym SJ, Ryu M-H, Kang HJ, et al. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer. Cancer Chemother Pharmacol. 2010;66:373-80.
16. Pasini F, de Manzoni G, Pedrazzani C, et al. High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy. Ann Oncol. 2005;16:1133-9. (Pubitemid 41418316)
17. Lorenzen S, Hentrich M, Haberl C, et al. Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol. 2007;18:1673-9. (Pubitemid 47506254)
18. Tebbutt NC, Cummins MM, Sourjina T, et al. Randomised, noncomparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer. 2010;102:475-81.
19. Al-Batran SE, Hartmann JT, Hofheinz R, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2008;19:1882-7.
20. Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26:1335-442.